Choroidal Neovascularization Market Report by Product Type, Diagnosis (Fluorescein Angiography, Indocyanine Green Angiography, Spectral Domain Optical Coherence Tomography, and Others), Treatment Type, Application, and Region 2024-2032
세계 맥락막 신생혈관 시장 규모는 2023년 65억 달러에 달했습니다. 향후 IMARC Group은 2024-2032년간 6.4%의 연평균 성장률(CAGR)을 보이며 2032년까지 116억 달러에 달할 것으로 예측했습니다.
맥락막 신생혈관(CNV)은 눈의 맥락막층에 신생혈관이 생겨서 맥락막과 망막색소상피(RPE)에 영향을 미치는 것을 말합니다. 그 증상으로는 지질 삼출, 망막하 혈액 및 액체, 중심 시야의 왜곡, 부풀어 오름, 흑점 등이 있습니다. 현재 CNV를 진단하기 위해 플루오레세인 혈관조영술(FA), 인도시아닌그린(ICG) 혈관조영술, 광간섭단층촬영(OCT) 등의 검사가 병행되고 있습니다. 결과에 따라 의사는 항혈관내피성장인자(VEGF) 약물, 열 레이저 치료, 광 역학 치료(PDT)를 처방하여 혈관의 성장을 막는다.
노화 황반변성(ARMD), 안구 히스토플라즈마증, 병적 근시, 혈관근육, 맥락막 파열, 맥락막 및 망막의 염증성 질환의 유병률 증가로 인해 시장이 성장하고 있습니다. 또한, 심각한 건강 상태에 취약한 노인 인구 증가는 시장 성장을 가속하는 또 다른 중요한 요인으로 작용하고 있습니다. 또한, 장기 지속형 항VEGF 약물의 채택과 함께 병용약물의 채택이 증가하면서 CNV 치료에 대한 세계 수요를 촉진하고 있습니다. 의료 인프라 개선과 연구 개발(R&D) 활동에 대한 투자 증가와 같은 다른 요인들도 시장 성장에 기여하고 있습니다.
본 보고서에서 다룬 주요 질문들
- 세계 맥락막 신생혈관 시장은 지금까지 어떻게 성장해왔고, 앞으로 어떻게 성장할 것인가?
- 코로나19는 세계 맥락막 신생혈관 시장에 어떤 영향을 미쳤는가?
- 주요 지역 시장은?
- 제품 유형별 시장 분석은?
- 진단별 시장 분석은?
- 치료 유형별 시장 현황은?
- 용도별 시장 분석은?
- 산업 가치사슬의 다양한 단계는?
- 업계의 주요 촉진요인과 과제는?
- 세계 맥락막 신생혈관 시장의 구조와 주요 진출 기업은?
- 업계의 경쟁은 어느 정도인가?
목차
제1장 서문
제2장 조사 범위와 조사 방법
- 조사 목적
- 이해관계자
- 데이터 소스
- 시장 추정
- 조사 방법
제3장 주요 요약
제4장 서론
제5장 세계의 맥락막 신생혈관 시장
- 시장 개요
- 시장 분석
- COVID-19의 영향
- 시장 예측
제6장 시장 분석 : 제품 유형별
제7장 시장 분석 : 진단별
- Fluorescein Angiography (FA)
- Indocyanine Green (ICG) Angiography
- Spectral Domain Optical Coherence Tomography (OCT)
- 기타
제8장 시장 분석 : 치료 유형별
- 혈관신생 억제제 주사
- 광선 역학 요법
- 레이저 광응고술
- 저선량 방사선 치료
- 수술
제9장 시장 분석 : 용도별
제10장 시장 분석 : 지역별
- 북미
- 아시아태평양
- 유럽
- 독일
- 프랑스
- 영국
- 이탈리아
- 스페인
- 러시아
- 기타
- 라틴아메리카
- 중동 및 아프리카
제11장 SWOT 분석
제12장 밸류체인 분석
제13장 Porter의 Five Forces 분석
- 개요
- 바이어의 교섭력
- 공급 기업의 교섭력
- 경쟁 정도
- 신규 진출업체의 위협
- 대체품의 위협
제14장 가격 분석
제15장 경쟁 구도
- 시장 구조
- 주요 기업
- 주요 기업 개요
- Bausch Health Companies Inc.
- Bayer AG
- Gilead Sciences, Inc.
- F. Hoffmann-La Roche AG
- MaaT Pharma
- Novartis AG
- Pfizer Inc.
- Quark Pharmaceuticals Inc.(SBI ALApharma Co., Limited)
- Regeneron Pharmaceuticals Inc.
- Sanwa Kagaku Kenkyusho Co. Ltd.(SUZUKEN CO., LTD.)
LSH
The global choroidal neovascularization market size reached US$ 6.5 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 11.6 Billion by 2032, exhibiting a growth rate (CAGR) of 6.4% during 2024-2032.
Choroidal neovascularization (CNV) refers to the creation of new blood vessels in the choroid layer of the eyes affecting the Bruch's membrane and retinal pigment epithelium (RPE). Its symptoms include lipid exudation, subretinal blood and fluid, and distortion, waviness and black spots in the central vision. At present, a combination of procedures, such as fluorescein angiography (FA), indocyanine green (ICG) angiography and optical coherence tomography (OCT) scanning, are utilized for diagnosing CNV. As per the results, doctors then prescribe anti-vascular endothelial growth factor (VEGF) drugs, thermal laser treatment and photodynamic therapy (PDT), to prevent the growth of the blood vessels.
The market is experiencing growth on account of the rising prevalence of age-related macular degeneration (ARMD), ocular histoplasmosis, pathologic myopia, angioid streaks, choroidal tears and inflammatory diseases of the choroid and retina. Moreover, the increasing geriatric population, which is more vulnerable to serious health conditions, is acting as another key factor bolstering the market growth. Furthermore, the growing adoption of combination drugs, along with the introduction of long-lasting anti-VEGF drugs, is propelling the demand for CNV treatments worldwide. Other factors, such as improving healthcare infrastructure and the increasing investments in research and development (R&D) activities, are also contributing to the growth of the market.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global choroidal neovascularization market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product type, type of diagnosis, treatment type and application.
Breakup by Product Type:
Intravenous
Intravitreal
Breakup by Type of Diagnosis:
Fluorescein Angiography (FA)
Indocyanine Green (ICG) Angiography
Spectral Domain Optical Coherence Tomography (OCT)
Others
Breakup by Treatment Type:
Angiogenesis Inhibitors Injection
Photodynamic Therapy
Laser photocoagulation
Low-dose Radiation Therapy
Surgery
Breakup by Application:
Extreme Myopia
Malignant Myopic Degeneration
Age-Related Developments
Breakup by Region:
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The report has also analysed the competitive landscape of the market with some of the key players being Bausch Health Companies Inc., Bayer AG, Gilead Sciences, Inc., F. Hoffmann-La Roche AG, MaaT Pharma, Novartis AG, Pfizer Inc., Quark Pharmaceuticals Inc. (SBI ALApharma Co. Limited), Regeneron Pharmaceuticals Inc. and Sanwa Kagaku Kenkyusho Co. Ltd. (Suzuken Co. Ltd.).
Key Questions Answered in This Report:
- How has the global choroidal neovascularization market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global choroidal neovascularization market?
- What are the key regional markets?
- What is the breakup of the market based on the product type?
- What is the breakup of the market based on the type of diagnosis?
- What is the breakup of the market based on the treatment type?
- What is the breakup of the market based on the application?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global choroidal neovascularization market and who are the key players?
- What is the degree of competition in the industry?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Choroidal Neovascularization Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Product Type
- 6.1 Intravenous
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Intravitreal
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
7 Market Breakup by Type of Diagnosis
- 7.1 Fluorescein Angiography (FA)
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Indocyanine Green (ICG) Angiography
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Spectral Domain Optical Coherence Tomography (OCT)
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 Others
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
8 Market Breakup by Treatment Type
- 8.1 Angiogenesis Inhibitors Injection
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Photodynamic Therapy
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Laser Photocoagulation
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
- 8.4 Low-dose Radiation Therapy
- 8.4.1 Market Trends
- 8.4.2 Market Forecast
- 8.5 Surgery
- 8.5.1 Market Trends
- 8.5.2 Market Forecast
9 Market Breakup by Application
- 9.1 Extreme Myopia
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
- 9.2 Malignant Myopic Degeneration
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
- 9.3 Age-Related Developments
- 9.3.1 Market Trends
- 9.3.2 Market Forecast
10 Market Breakup by Region
- 10.1 North America
- 10.1.1 United States
- 10.1.1.1 Market Trends
- 10.1.1.2 Market Forecast
- 10.1.2 Canada
- 10.1.2.1 Market Trends
- 10.1.2.2 Market Forecast
- 10.2 Asia Pacific
- 10.2.1 China
- 10.2.1.1 Market Trends
- 10.2.1.2 Market Forecast
- 10.2.2 Japan
- 10.2.2.1 Market Trends
- 10.2.2.2 Market Forecast
- 10.2.3 India
- 10.2.3.1 Market Trends
- 10.2.3.2 Market Forecast
- 10.2.4 South Korea
- 10.2.4.1 Market Trends
- 10.2.4.2 Market Forecast
- 10.2.5 Australia
- 10.2.5.1 Market Trends
- 10.2.5.2 Market Forecast
- 10.2.6 Indonesia
- 10.2.6.1 Market Trends
- 10.2.6.2 Market Forecast
- 10.2.7 Others
- 10.2.7.1 Market Trends
- 10.2.7.2 Market Forecast
- 10.3 Europe
- 10.3.1 Germany
- 10.3.1.1 Market Trends
- 10.3.1.2 Market Forecast
- 10.3.2 France
- 10.3.2.1 Market Trends
- 10.3.2.2 Market Forecast
- 10.3.3 United Kingdom
- 10.3.3.1 Market Trends
- 10.3.3.2 Market Forecast
- 10.3.4 Italy
- 10.3.4.1 Market Trends
- 10.3.4.2 Market Forecast
- 10.3.5 Spain
- 10.3.5.1 Market Trends
- 10.3.5.2 Market Forecast
- 10.3.6 Russia
- 10.3.6.1 Market Trends
- 10.3.6.2 Market Forecast
- 10.3.7 Others
- 10.3.7.1 Market Trends
- 10.3.7.2 Market Forecast
- 10.4 Latin America
- 10.4.1 Brazil
- 10.4.1.1 Market Trends
- 10.4.1.2 Market Forecast
- 10.4.2 Mexico
- 10.4.2.1 Market Trends
- 10.4.2.2 Market Forecast
- 10.4.3 Others
- 10.4.3.1 Market Trends
- 10.4.3.2 Market Forecast
- 10.5 Middle East and Africa
- 10.5.1 Market Trends
- 10.5.2 Market Breakup by Country
- 10.5.3 Market Forecast
11 SWOT Analysis
- 11.1 Overview
- 11.2 Strengths
- 11.3 Weaknesses
- 11.4 Opportunities
- 11.5 Threats
12 Value Chain Analysis
13 Porters Five Forces Analysis
- 13.1 Overview
- 13.2 Bargaining Power of Buyers
- 13.3 Bargaining Power of Suppliers
- 13.4 Degree of Competition
- 13.5 Threat of New Entrants
- 13.6 Threat of Substitutes
14 Price Analysis
15 Competitive Landscape
- 15.1 Market Structure
- 15.2 Key Players
- 15.3 Profiles of Key Players
- 15.3.1 Bausch Health Companies Inc.
- 15.3.1.1 Company Overview
- 15.3.1.2 Product Portfolio
- 15.3.1.3 Financials
- 15.3.1.4 SWOT Analysis
- 15.3.2 Bayer AG
- 15.3.2.1 Company Overview
- 15.3.2.2 Product Portfolio
- 15.3.2.3 Financials
- 15.3.2.4 SWOT Analysis
- 15.3.3 Gilead Sciences, Inc.
- 15.3.3.1 Company Overview
- 15.3.3.2 Product Portfolio
- 15.3.3.3 Financials
- 15.3.3.4 SWOT Analysis
- 15.3.4 F. Hoffmann-La Roche AG
- 15.3.4.1 Company Overview
- 15.3.4.2 Product Portfolio
- 15.3.4.3 SWOT Analysis
- 15.3.5 MaaT Pharma
- 15.3.5.1 Company Overview
- 15.3.5.2 Product Portfolio
- 15.3.6 Novartis AG
- 15.3.6.1 Company Overview
- 15.3.6.2 Product Portfolio
- 15.3.6.3 Financials
- 15.3.6.4 SWOT Analysis
- 15.3.7 Pfizer Inc.
- 15.3.7.1 Company Overview
- 15.3.7.2 Product Portfolio
- 15.3.7.3 Financials
- 15.3.7.4 SWOT Analysis
- 15.3.8 Quark Pharmaceuticals Inc. (SBI ALApharma Co., Limited)
- 15.3.8.1 Company Overview
- 15.3.8.2 Product Portfolio
- 15.3.9 Regeneron Pharmaceuticals Inc.
- 15.3.9.1 Company Overview
- 15.3.9.2 Product Portfolio
- 15.3.9.3 Financials
- 15.3.9.4 SWOT Analysis
- 15.3.10 Sanwa Kagaku Kenkyusho Co. Ltd. (SUZUKEN CO., LTD.)
- 15.3.10.1 Company Overview
- 15.3.10.2 Product Portfolio
